We reply within one business dayGet my quote
Vitiligo: US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Vitiligo: the short answer
The US FDA has approved one medicine on this page for vitiligo, each for specific patients. One of them is on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Opzelura.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is vitiligo?
Vitiligo causes white patches on the skin when the cells that give skin its color (melanocytes) are destroyed. Hair in these areas may also turn white. It is generally considered an autoimmune disorder and is more common in people with other autoimmune diseases.[1, 2]
Generalized (nonsegmental) vitiligo is the most common form, with patches on many parts of the body, often the face, neck, hands and around body openings. Segmental vitiligo affects one side of the body. Patches can spread, stay stable or sometimes improve.[2]
Treatments include medicines, light therapy and surgery. Sunscreen protects the skin and cosmetics can cover patches. In the US, a JAK inhibitor cream is approved for nonsegmental vitiligo in patients 12 years and older.[1, 3]
Vitiligo in the Gulf
A six-year study at a Saudi center identified 1,555 vitiligo cases, a prevalence of 0.235% among patients, with 60% female. In the detailed group of 573 patients, 49% had onset before age 20 and 42% reported a family history.[4]
US FDA-approved medicines for vitiligo
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Opzelura (ruxolitinib)
FDA-approved for topical treatment of nonsegmental vitiligo in adults and children 12 years and older. It is a cream (ruxolitinib 1.5%) applied to affected skin.[3]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Oman, Jordan, Lebanon
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[7, 8] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for vitiligo
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for vitiligo?
Yes. The medicine on this page has US FDA approval for specific groups of patients: Opzelura. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Opzelura available in Saudi Arabia or the UAE?
Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Opzelura?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Is vitiligo contagious?
No. MedlinePlus explains that vitiligo happens when pigment cells are destroyed, and it is linked with autoimmune disease, not infection.
Does vitiligo run in families?
It can. MedlinePlus notes it might run in families, and in the Saudi study 42% of patients reported a family history.
Sources for the last two answers: [1] [1, 4]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus (US National Library of Medicine): Vitiligo
- MedlinePlus Genetics (US National Library of Medicine): Vitiligo
- DailyMed (US National Library of Medicine): Opzelura (ruxolitinib) US prescribing information, version published 15 July 2026
- AlJasser et al. Vitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients. Clin Cosmet Investig Dermatol 2024 (PubMed 39712943)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Psoriasis
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.